Wednesday, June 10, 2026

pharma Β· Cystic Fibrosis Β· Hepatitis C

Vertex Pharmaceuticals (Australia)

Vertex Pharmaceuticals (Australia) clinical programs β€” 50 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
Status
Public
HQ
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
Founded
1989
Employees
6,304
Programs
159
Drugs
64
Patents
991
Intelligence Β· Clinical Programs

Vertex Pharmaceuticals (Australia) projects

50 ClinicalTrials.gov programs sponsored by Vertex Pharmaceuticals (Australia).

Vertex Pharmaceuticals (Australia) has 50 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. VX22-445-123

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial
  2. VX24-AIS-D10

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Vertex Pharmaceuticals (Australia) have?

50 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.